Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Vessby, B; Kostner, G; Lithell, H; Thomis, J.
Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). A dose-response study of the effects of cholestyramine in hypercholesterolaemia.
Atherosclerosis. 1982; 44(1):61-71
Doi: 10.1016/0021-9150(82)90053-3
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Kostner Gerhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Nineteen hypercholesterolaemic patients were randomly treated with either 16 or 8 g cholestyramine with a changeover after 6 weeks for a second 6-week period. During a third consecutive 6-week period all patients received 4 g cholestyramine daily. The low density lipoprotein (LDL) cholesterol and triglyceride concentrations decreased significantly (- 11%, - 21% and - 26% for LDL cholesterol on 4, 8 and 16 g, respectively) with a dose-response effect. However, the increase from 8 g to 16 g only caused a modest additional reduction of the lipid levels. The serum concentration of apolipoprotein (apo) B was correlated to the LDL cholesterol and decreased similarly in a dose-response fashion. However, the average reduction of apo B was less pronounced (- 4%, - 13% and - 17% on 4, 8 and 16 g of cholestyramine, respectively) resulting in a significant change of the apo B/LDL cholesterol ratio during treatment. There was a significant increase of the high density lipoprotein (HDL) cholesterol concentration, which was similar at all dose levels. Also, the apo A-I concentration in serum increased significantly but the relative decrease was less pronounced than that of HDL cholesterol, causing a significant decrease of the apo A-I/HDL cholesterol ratio. The apo A-II concentration in serum was unchanged or slightly decreased and the apo A-I/apo A-II ratio increased significantly.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Apolipoprotein A-I -
- Apolipoprotein A-II -
- Apolipoproteins - blood
- Apolipoproteins B - blood
- Cholestyramine - therapeutic use
- Dose-Response Relationship, Drug - therapeutic use
- Female - therapeutic use
- Humans - therapeutic use
- Hypercholesterolemia - drug therapy
- Lipoprotein(a) - drug therapy
- Lipoproteins - blood
- Lipoproteins, LDL - blood
- Lipoproteins, VLDL - blood
- Male - blood
- Middle Aged - blood